Pilot study of etanercept in patients with refractory juvenile dermatomyositis

Arthritis Care and Research

Volumn 66, Issue 5, 2014, Pages 783-787

  Rouster Stevens, Kelly A ^a   Ferguson, Lori ^b   Morgan, Gabrielle ^b   Huang, Chiang Ching ^c   Pachman, Lauren M ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ann and Robert H Lurie Children's Hospital   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CAPILLAROSCOPY; CHILD; CHILDHOOD MYOSITIS ASSESSMENT SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG WITHDRAWAL; EVALUATION STUDY; FEMALE; HUMAN; JUVENILE DERMATOMYOSITIS; MALAR FLUSH; MALE; MOUTH DISEASE; NAILFOLD CAPILLAROSCOPY; OUTCOME ASSESSMENT; PILOT STUDY; RASH; RATING SCALE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; CHILD; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84899112382     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22198     Document Type: Article

References (18)

1. Lundberg IE,. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000; 2: 216-24.
2. Fedczyna TO, Lutz J, Pachman LM,. Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFα-308A allele. Clin Immunol 2001; 110: 236-9.
3. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43: 2368-77.
4. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 2010; 62: 219-25.
5. Efthimious P, Schwartzman S, Kagen LJ,. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65: 1233-6. (Pubitemid 44277404)
6. Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor α: preliminary observations. Eur Neurol 2003; 50: 10-5. (Pubitemid 36736963)
7. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA,. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47: 887-80.
8. Muscle Study Group. A randomized, pilot trail of etanercept in dermatomyositis. Ann Neurol 2011; 70: 427-36.
9. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
10. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
11. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM,. Disease Activity Score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 7-15. (Pubitemid 36286124)
12. Charles PJ, Smeenk RJ, De Jong J, Feldman M, Maini RN,. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
13. Manna SK, Mukhopadhyay A, Aggarwal BB,. IFN-α suppresses activation of nuclear transcription factors NF-κ B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol 2000; 165: 4927-34.
14. Iannone F, Scioscia C, Falappone P, Covelli M, Lapadula G,. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33: 1802-4. (Pubitemid 44373214)
15. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67: 1670-7.
16. Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM,. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol 2011; 147: 831-5.
17. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al, and the RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
18. Arabshahi B, Silverman RA, Jones OY, Rider RG,. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012; 160: 520-2.